CClinicalTrials.gg
CompletedNCT01287299PANSUpdated Nov 24, 2020

Glycemic Load, Metabolism & Obesity in Pregnancy

An interventional study of Low Glycemic Load diet and Low Fat Diet in Obesity and Insulin Resistance, sponsored by UCSF Benioff Children's Hospital Oakland. Completed at 1 site in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by UCSF Benioff Children's Hospital Oakland · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of the study is to determine if a low glycemic load diet reduces the gain of body fat and insulin resistance during the last half of pregnancy in obese women.

Read the detailed description

Obese women will be recruited to participate in the study between 14-18 weeks gestation. After determining usual dietary intakes, visceral fat thickness, and the metabolic response to a 100g oral glucose tolerance test (OGTT) at 20 weeks gestation, 45 of the women will be randomly assigned to a low glycemic load (GL) diet and 65 women to a regular low fat diet (current standard care). They will follow their assigned diet for the last 20 weeks of gestation. A dietitian will advise the women and will monitor them throughout the study. At 28 and 34 weeks gestation, the women will come to the General Clinical Research Center (GCRC) at San Francisco General Hospital in the fasting state and the hormonal and metabolic response will be measured to another 100g oral glucose tolerance test (OGTT), and total body fat will be measured. Additional measurements include: 1) longitudinal measurements of maternal visceral fat thickness and fetal size and adiposity at 20 and 34 weeks gestation by ultrasound, 2) collection of cord blood and placental tissue, and 3) measurement of neonatal body composition by dual-energy x-ray absorptiometry and anthropometry at 2-3 weeks of age. Birth outcome data for mother and infant will be collected. To determine the metabolic response to the study diet, 25 women from each of the two diet groups will be assigned to a metabolic subsample for measuring rates of hepatic glucose production and lipolysis at 34 weeks.

02

Conditions studied

  • Obesity
  • Insulin Resistance

Keywords

  • pregnancy
  • obesity
  • diet glycemic load
  • body composition
  • body fat
  • gestational weight gain
  • insulin resistance
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 64 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

UCSF Benioff Children's Hospital Oakland is the lead sponsor of 53 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • >35% body fat
  • 18 to 40 years of age
  • speak English or Spanish

Exclusion criteria

Exclusion Criteria:

  • have diabetes prior to pregnancy
  • diagnosed with GDM in current pregnancy
  • smoke
  • abuse alcohol or drugs
  • have a metabolic disease
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Low Glycemic Load Diet

    Counseled to consume a diet with a low or higher intake of carbohydrate sources that cause rapid or significant intakes in blood glucose. The average glycemic load of the diet should be less than 55 per 1000 calories or greater than 55 per 1000 calories.

    Other: Low Glycemic Load diet

  • Experimental
    Low Fat Diet

    Pregnant women were counseled to consume a diet providing less that 25% of the energy as fat.

    Other: Low Fat Diet

Interventions

  • OtherLow Glycemic Load diet

    Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.

    Also known as: LGL Diet

  • OtherLow Fat Diet

    Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.

    Also known as: LF Diet

06

What researchers measure

Primary outcomes

  1. maternal body fat gain

    Changes in total body fat as measured by air displacement between 20 to 34 weeks gestation

    Time frame: 20-34 weeks gestation

Secondary outcomes

  1. Insulin Resistance

    Changes in insulin resistance measured during an oral glucose tolerance test between 20 to 34 weeks gestation.

    Time frame: 20-34 weeks gestation

07

Study locations

1 site
  • San Francisco General Hospital
    San Francisco, California 94110, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01287299
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Collaborators
University of California, San Francisco, University of California, Davis, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Responsible party
Sponsor
First posted
Feb 1, 2011
Start date
Jul 2005
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Nov 24, 2020

Study contacts

Janet C King, Ph.D.
principal investigator · UCSF Benioff Children's Hospital Oakland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion